tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Passage Bio reports Q3 EPS ($2.44), consensus ($2.97)
PremiumThe FlyPassage Bio reports Q3 EPS ($2.44), consensus ($2.97)
1M ago
Passage Bio’s PBFT02 Study: A Promising Step in Gene Therapy for Dementia
Premium
Company Announcements
Passage Bio’s PBFT02 Study: A Promising Step in Gene Therapy for Dementia
2M ago
Optimistic Outlook for Passage Bio’s PBFT02: Promising Data and Potential FDA Support
Premium
Ratings
Optimistic Outlook for Passage Bio’s PBFT02: Promising Data and Potential FDA Support
2M ago
Passage Bio reports Q2 EPS ($2.96) vs ($5.09) last year
PremiumThe FlyPassage Bio reports Q2 EPS ($2.96) vs ($5.09) last year
4M ago
Passage Bio expects cash to fund operations into Q1 of 2027
Premium
The Fly
Passage Bio expects cash to fund operations into Q1 of 2027
4M ago
Passage Bio Regains Nasdaq Compliance with Stock Price
Premium
Company Announcements
Passage Bio Regains Nasdaq Compliance with Stock Price
5M ago
Optimistic Buy Rating for Passage Bio’s PBFT02: Promising Efficacy and Managed Safety Concerns
PremiumRatingsOptimistic Buy Rating for Passage Bio’s PBFT02: Promising Efficacy and Managed Safety Concerns
6M ago
Passage Bio’s Promising Clinical Trial Results and Strategic Adjustments Justify Buy Rating
Premium
Ratings
Passage Bio’s Promising Clinical Trial Results and Strategic Adjustments Justify Buy Rating
6M ago
Passage Bio Releases Promising Interim Data for PBFT02
Premium
Company Announcements
Passage Bio Releases Promising Interim Data for PBFT02
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100